Highest-materiality recent filing
Entered into Sales Agreement with TD Securities (USA) LLC for at-the-market offering of up to $250M of common stock.
Anteris raises $320M, Q1 cash burn $28.7M; PARADIGM trial enrols in US
Net operating cash outflows of $28.7M for Q1 2026, funding PARADIGM Trial and manufacturing scale-up.
Anteris Technologies signs 11-year lease for 181,436 sq ft in Brooklyn Park, MN
Lease executed April 23, 2026; initial term from Sept 1, 2026 to Aug 31, 2037.
Anteris reports FY2025 revenue down 29%, net loss widens to $94M; starts PARADIGM trial
FY2025 revenue $1.9M (-29% YoY); net loss $94.1M (23% wider); cash used in ops $77.8M.
Anteris raises ~$320M via public offering and Medtronic PIPE for DurAVR THV trial
Public offering of 40M shares at $5.75 (including full over-allotment); gross proceeds ~$230M.
Medtronic makes $90M strategic investment in Anteris; combined $320M capital raise
Medtronic invested $90M in Anteris via stock purchase; Anteris also completed an underwritten common stock offering for total gross proceeds of $320M.
Anteris reports positive 30-day DurAVR THV outcomes in 100 small-annuli patients
No valve-related mortality and no moderate/severe paravalvular leak at 30 days.
Anteris reports Q3 2025 cash burn; FDA OK to start PARADIGM trial in US
FDA approved U.S. recruitment for PARADIGM Trial in Nov 2025; first patients treated in Denmark in Oct 2025.
Anteris obtains FDA approval to initiate PARADIGM pivotal trial for DurAVR THV
FDA approved global IDE trial for DurAVR THV in severe aortic stenosis patients.
Anteris enrolls & treats first patients in DurAVR THV global pivotal trial
First patients enrolled and successfully treated in PARADIGM Trial for DurAVR THV in severe calcific aortic stenosis.
Anteris Technologies raises ~$25M via unregistered placement of shares, CDIs, and warrants
Sold 2,244,896 shares at $4.90/share with 5-year warrants at $7.50; 2,788,064 CDIs at A$7.50 with warrants at A$11.50.
Anteris gets Danish clearance to start DurAVR THV global pivotal trial
Danish Medicines Agency clears Anteris to initiate DurAVR THV PARADIGM Trial for severe calcific aortic stenosis.
Anteris delays PARADIGM pivotal trial enrollment to Q4 2025 after FDA request
Patient enrollment in PARADIGM trial now expected Q4 2025, previously Q3 2025.
Anteris Technologies reports Q2 2025 net loss $42.7M; cash $28.4M; 130 DurAVR implants
Revenue from ordinary activities $1.17M for six months, down 16% YoY; net loss $42.7M, up 22% YoY.
Anteris Technologies gets ASX waiver from Listing Rule 7.1 on securities issuance
ASX granted waiver from Listing Rule 7.1, allowing above-15% issuance without stockholder approval.
Anteris Q1 net loss $21.9M (up 36%); sales $0.6M (-27%); DurAVR IDE submitted
Net loss $21.9M vs $16.2M a year ago; revenue $0.6M down 27% on lower tissue demand.
Anteris reaches 100 patients treated with DurAVR THV; strong one-year safety and efficacy data
Over 100 patients treated with DurAVR THV, including de novo, valve-in-valve, and bicuspid cases.
Anteris DurAVR THV reports zero PPM at one year in small annuli patients
One-year hemodynamic data: EOA 2.1±0.2 cm², mean gradient 8.6±2.6 mmHg, DVI 0.58 (n=65).
Anteris Technologies posts FY2024 net loss of $76M; auditor flags going concern doubt
Net loss after tax $76.0M vs $46.8M in 2023; revenue flat at $2.7M.
Anteris closes IPO raising $80M net; completes reorganization with ATL
IPO of 14.8M shares at $6.00/sh closed Dec 16, 2024; net proceeds $80.0M.
On May 11, 2026 (May 12, 2026 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board.
On May 11, 2026 (May 12, 2026 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board.
Mr. Moss will serve as a Class I Director, with a term expiring at the Company's 2025 annual meeting of stockholders and will serve on the Nominating and Corporate Governance Committee of the Board.
Mr. Roberts will serve as a Class III Director, with a term expiring at the Company’s 2027 annual meeting of stockholders and will serve on the Audit and Risk Committee and the Compensation Committee of the Board.
On March 5, 2025 (March 6, 2025 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed David St Denis as the Company’s President and as a Class II director of the Board, effective immediately.
On March 5, 2025 (March 6, 2025 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed David St Denis as the Company’s President and as a Class II director of the Board, effective immediately.
Max materiality 0.95 · Median 0.62 · Most common event other_material